Charles Coyne, MD
Family Medicine · Warrenton, MONPI 1295048031
Payments from drug & device makers
Across 366 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$943
- Lilly USA, LLC$829
- Novo Nordisk$412
- Boehringer Ingelheim$371
- Teva Pharmaceuticals USA, Inc.$310
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 47 | $1,016 |
| AbbVie(2 entities) | 58 | $943 |
| Lilly USA, LLC | 49 | $829 |
| Novo Nordisk | 27 | $412 |
| Boehringer Ingelheim | 23 | $371 |
| Teva Pharmaceuticals USA, Inc. | 19 | $310 |
| Amgen | 17 | $265 |
| Merck | 16 | $246 |
| Pfizer | 13 | $219 |
| Organon | 2 | $173 |
| GSK | 11 | $161 |
| Johnson & Johnson | 10 | $144 |
| Astellas Pharma US Inc | 7 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $124 |
| Otsuka America Pharmaceutical, Inc. | 7 | $113 |
| Eisai Inc. | 7 | $103 |
| Exact Sciences | 4 | $72 |
| Amarin Pharma, Inc. | 4 | $58 |
| Sanofi Pasteur Inc. | 4 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Biohaven Pharmaceuticals, Inc. | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Novartis | 3 | $44 |
| Electromed, Inc. | 6 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Mylan Specialty L.p. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Corcept Therapeutics | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 2 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,195 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $200,216 |
| JardianceEmpagliflozin | 148 | $158,111 |
| EliquisApixaban | 121 | $122,773 |
| MounjaroTirzepatide | 37 | $52,781 |
| TrulicityDulaglutide | 34 | $52,610 |
| MyrbetriqMirabegron | 63 | $52,227 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $45,000 |
| FarxigaDapagliflozin Propanediol | 31 | $34,282 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $30,421 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $18,865 |
| JanuviaSitagliptin Phosphate | 18 | $18,176 |
| XareltoRivaroxaban | 12 | $12,834 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $11,052 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,020 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $8,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $412 | $200,216134 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $371 | $166,457164 claims |
| PfizerEliquis | $219 | $122,773121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $829 | $105,39171 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $1,016 | $79,839105 claims |
| Astellas Pharma US IncMyrbetriq | $129 | $52,22763 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $161 | $33,56174 claims |
| MerckJanuvia, Belsomra | $246 | $23,80231 claims |
| Johnson & JohnsonXarelto | $144 | $12,83412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Warrenton
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.